Supporting the aerobic glycolysis of cancer cells first reported by Otto Warburg in the 1950s [68], it was recently established that CD133 expression is associated with high cellular glucose metabolism: CD133 was found to be a glucose responsive gene in L6 myotubes [11] and CD133 expression to be concomitant to high glucose cellular uptake in U251 glioma cells [12]. This evidence concerns the gene PROM1 and central nervous system cancer.